Research programme: cardiovascular disease - Collateral Therapeutics/University of California
Alternative Names: Cardiovascular disease research programme - Collateral Therapeutics/University of CaliforniaLatest Information Update: 28 Sep 2006
At a glance
- Originator University of California at San Francisco
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Ischaemic heart disorders
Most Recent Events
- 28 Sep 2006 Discontinued - Preclinical for Heart failure in USA (unspecified route)
- 28 Sep 2006 Discontinued - Preclinical for Ischaemic heart disorders in USA (unspecified route)
- 17 Jul 2002 Schering AG has acquired Collateral Therapeutics